Gabapentin for Spinal Stenosis Pain and Radiculopathy

Efficacy in Radiculopathy

Gabapentin is associated with small, short-term benefits in patients with radiculopathy and has not been directly compared with other medications or treatments 1
For chronic radicular back pain, studies report inconsistent findings for gabapentin (doses titrated up to 1200-3600 mg/day) versus placebo, with effects on pain intensity ranging from 0.3 to 1.9 points on a 0-10 point scale 2

For neuropathic pain conditions, the American Academy of Neurology recommends that gabapentinoids, serotonin-norepinephrine reuptake inhibitors (SNRIs), sodium channel blockers, and tricyclic antidepressants (TCAs) could all be considered 3
A recent head-to-head trial suggested therapeutic equivalency for TCAs, SNRIs, and gabapentinoids in the treatment of neuropathic pain, and supported the role of combination therapy over monotherapy 3

Adverse effects of gabapentinoids may be more severe in older individuals and may be attenuated by lower starting doses and more gradual titration 3
Gabapentin is not FDA-approved for treatment of low back pain (with or without radiculopathy), and if used, a time-limited course of therapy is recommended 1

Most medication trials evaluated patients with nonspecific low back pain or mixed populations with and without sciatica, with limited evidence specifically for patients with spinal stenosis or radiculopathy 1, 2
Extended courses of medications should generally be reserved for patients clearly showing continued benefits from therapy without major adverse events 1

The American College of Physicians recommends NSAIDs, such as naproxen, as first-line treatment for radiculopathy due to their moderate efficacy and better safety profile compared to other options 4, 5
NSAIDs primarily target the inflammatory component of radicular pain 5
NSAIDs should be used at the lowest effective dose to minimize gastrointestinal and cardiovascular risks 5
Gabapentin shows small to moderate short-term benefits for radicular pain and is particularly effective for the neuropathic component of radiculopathy 5
The American Academy of Neurology suggests that gabapentin may provide benefits in terms of pain alleviation and improved quality of life in patients with chronic radiculopathy, although the strength of evidence is moderate 5

Lumbosacral radiculopathy appears to be relatively refractory to existing first- and second-line medications, with limited high-quality evidence on the best nonoperative therapy for cervical radiculopathy specifically 6, 7
Evidence suggests that medications with established efficacy in other neuropathic pain conditions might not have the same efficacy in radiculopathy, highlighting the need for further research 7

The initial approach to managing cervical and lumbar radiculopathy involves starting with naproxen to target the inflammatory component, adding gabapentin for the neuropathic component, and using cyclobenzaprine for short-term relief of muscle spasm, with ongoing monitoring and adjustment as needed 5